CORRECTION Open Access



Correction to: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study

Li Jiang^{1,2}, Jie Zhu², Xue Chen^{1,2}, Yi Wang², Lei Wu², Gang Wan², Yongtao Han³, Xuefeng Leng^{3*} and Qifeng Wang^{2*}

Radiation Oncology (2022) 17:218 https://doi.org/10.1186/s13014-022-02190-4

After publication of this article [1], the authors reported that in this article Li Jiang was incorrectly denoted as a corresponding author.

The original article [1] has been corrected.

The online version of the original article can be found at https://doi.org/10.1186/s13014-022-02190-4.

*Correspondence: Lin Peng penglinms@126.com Qifeng Wang littlecancer@163.com

¹School of Medicine, Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, Chengdu, Sichuan 610041, China

²Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, Sichuan 610041, China

³Department of Thoracic Surgery, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China

References

Jiang L, Zhu J, Chen X, Wang Y, Wu L, Wan G, et al. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study. Radiat Oncol. 2022;17:218. https://doi.org/10.1186/s13014-022-02190-4

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 05 May 2023



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.